SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-314363
Filing Date
2019-12-16
Accepted
2019-12-16 07:00:40
Documents
12
Period of Report
2019-12-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d846868d8k.htm   iXBRL 8-K 24195
  Complete submission text file 0001193125-19-314363.txt   146117

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20191213.xsd EX-101.SCH 3066
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20191213_lab.xml EX-101.LAB 18141
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20191213_pre.xml EX-101.PRE 11406
9 EXTRACTED XBRL INSTANCE DOCUMENT d846868d8k_htm.xml XML 3359
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 191285840
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences